logo-loader

Amryt Pharma’s Lojuxta ‘bad’ cholesterol treatment to be made available in France in early 2019

Published: 02:50 17 Oct 2018 EDT

Lojuxta is a treatment for Homozygous Familial Hypercholesterolaemia which causes high levels of ‘bad’ cholesterol
Lojuxta is a treatment for Homozygous Familial Hypercholesterolaemia which causes high levels of ‘bad’ cholesterol

Amryt Pharma PLC’s (LON:AMYT) flagship Lojuxta drug will soon be available in all five of the EU’s largest markets after French officials agreed to reimburse patients receiving the ‘bad’ cholesterol treatment.

The drug is expected to be made available to French patients suffering from the rare condition – known in the medical sphere as Homozygous Familial Hypercholesterolaemia (HoFH) – from early next year.

READ: Lojuxta to be made available on the NHS

The approval means that Lojuxta is available across all five of the EU's major markets – France, the UK, Italy, Germany and Spain.

“A clear aim in continuing the positive momentum in Lojuxta revenues is to ensure reimbursement in our core territories,” said chief executive Joe Wiley.

“Following closely on from our recent approval with the NHS in England, where we have already started treating patients, we are now very  pleased to be able to make Lojuxta available to adult HoFH patients in France.”

HoFH is a rare life-threatening disorder that causes abnormally high levels of low-density lipoprotein (LDL) cholesterol.

Clinical trials showed Lojuxta can reduce the production and uptake of this ‘bad’ cholesterol, helping sufferers to get their cholesterol levels down to acceptable levels.

Novo Resources sees substantial upside potential at Nunyerry

Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO) co-chair and acting CEO Mike Spreadborough joins Jonathan Jackson in the Proactive studio to discuss promising gold outcomes from recent reanalysis of drill intercepts in a 2023 program at Nunyerry North in Western Australia. Using advanced...

10 hours, 9 minutes ago